> Merkliste Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp: E-Artikel Titel: DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies Beteiligte: Seidl, Sonja; Ackermann, Jutta; Kaufmann, Hannes; Keck, Andrea; Nösslinger, Thomas; Zielinski, Christoph C.; Drach, Johannes; Zöchbauer‐Müller, Sabine Erschienen: Wiley, 2004 Erschienen in: Cancer Sprache: Englisch DOI: 10.1002/cncr.20295 ISSN: 0008-543X; 1097-0142 Schlagwörter: Cancer Research ; Oncology Entstehung: Anmerkungen: Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Silencing of tumor suppressor genes (TSG) by aberrant methylation (referred to as <jats:italic>methylation</jats:italic>) contributes to the pathogenesis of various human malignancies. However, little is known about the methylation of known and putative TSGs in monoclonal gammopathies. Thus, the authors investigated the methylation frequencies of 10 genes in patients with monoclonal gammopathies.</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>The methylation patterns of the genes <jats:italic>p16</jats:italic><jats:sup><jats:italic>INK4a</jats:italic></jats:sup> (<jats:italic>p16</jats:italic>), tissue inhibitor of metalloproteinase 3 (<jats:italic>TIMP3</jats:italic>), <jats:italic>p15</jats:italic><jats:sup><jats:italic>INK4b</jats:italic></jats:sup> (<jats:italic>p15</jats:italic>), E‐cadherin (<jats:italic>ECAD</jats:italic>), death‐associated protein kinase (<jats:italic>DAPK</jats:italic>), <jats:italic>p73</jats:italic>, RAS‐association domain family 1A (<jats:italic>RASSF1A</jats:italic>), <jats:italic>p14</jats:italic>, O<jats:sup>6</jats:sup>‐methylguanine DNA methyltransferase (<jats:italic>MGMT</jats:italic>), and retinoid acid receptor β2 (<jats:italic>RARβ</jats:italic>) were determined in patients with monoclonal gammopathy of undetermined significance (MGUS; <jats:italic>n</jats:italic> = 29), smoldering multiple myeloma (SMM; <jats:italic>n</jats:italic> = 5), multiple myeloma (MM; <jats:italic>n</jats:italic> = 113), or plasma cell leukemia (PCL; <jats:italic>n</jats:italic> = 7) by methylation‐specific polymerase chain reaction analysis.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Methylation frequencies for <jats:italic>p16</jats:italic>, <jats:italic>TIMP3</jats:italic>, <jats:italic>p15</jats:italic>, <jats:italic>ECAD</jats:italic>, <jats:italic>DAPK</jats:italic>, <jats:italic>p73</jats:italic>, <jats:italic>RASSF1A</jats:italic>, <jats:italic>p14</jats:italic>, <jats:italic>MGMT</jats:italic>, and <jats:italic>RARβ</jats:italic> were as follows: 28%, 35%, 10%, 0%, 17%, 21%, 14%, 14%, 7%, and 0%, respectively, in patients with MGUS and 36%, 29%, 27%, 27%, 22%, 15%, 15%, 9%, 4%, and 0%, respectively, in patients with MM. Methylation of at least 1 of these genes was detected in 79% of patients with MGUS and in 80% of patients with MM. Although methylation of <jats:italic>ECAD</jats:italic> was not detected in patients with MGUS, it was observed frequently in patients with MM and with even greater frequency in patients with PCL. It is noteworthy that an association was found between <jats:italic>ECAD</jats:italic> methylation and poor prognostic markers in patients with MM.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>Methylation of certain genes can be detected frequently in patients with monoclonal gammopathies. The current data suggest that methylation of <jats:italic>ECAD</jats:italic> is a marker of disease progression in patients with MM and PCL. Cancer 2004. © 2004 American Cancer Society.</jats:p></jats:sec> Zugangsstatus: Freier Zugang